Seng Chin Mah is an independent healthcare advisor with over 30 years’ experience in the Pharma and Biotech industry, both in public and privately held companies. 

Dr. Mah is the Chairman of BioVersys AG (a SIX-listed company) and a member of the board of OSR Holdings Inc (a NASDAQ-listed company) and Vaccentis AG. He was formerly the Chief Executive Officer of the Canyon Pharmaceuticals Group AG where he transacted a corporate inversion of a US registered company to Switzerland. 

Prior to Canyon Pharmaceuticals, he was the Head of Development of the Integration Office during the integration of Chiron into Novartis and has previously held positions including the Global Head of Clinical Safety and Epidemiology and Head of Drug Regulatory Affairs Europe. He also had oversight responsibility for Clinical Quality Assurance across the Novartis group. Dr. Mah was also a member of the Novartis Corporate Executive Group and a member of the board of directors for Novartis Europharm Ltd in the UK. During his tenure with Novartis and Ciba, he has driven transformational programs, managed large global organizations, and achieved significant business results such as the numerous global registrations of major products. Dr. Mah has worked extensively on both development projects and marketed products. He has held numerous research and academia positions. 

Dr. Mah is an award-winning CEO of a biotech – The Frost & Sullivan 2011 Product Differentiation Excellence Award in Parenteral Anticoagulants recognized Canyon Pharmaceuticals Group AG for the development and launch of Iprivask® (desirudin for injection). He subsequently effected an asset transaction of the product. He possesses deep knowledge in strategic decision-making within the Pharma and Biotech industry, late-stage clinical development, regulatory and business experience as well as people development skills.